Opus Genetics Files 8-K on Shareholder Vote Matters

Ticker: IRD · Form: 8-K · Filed: May 1, 2025 · CIK: 1228627

Sentiment: neutral

Topics: shareholder-vote, corporate-governance

TL;DR

Opus Genetics had a shareholder vote on 4/30, details to follow.

AI Summary

Opus Genetics, Inc. filed an 8-K on May 1, 2025, reporting on matters submitted to a vote of security holders as of April 30, 2025. The filing does not contain specific details about the vote outcomes or the matters voted upon, only that a submission occurred.

Why It Matters

This filing indicates that Opus Genetics held a shareholder vote, which could signal significant corporate actions or changes that may impact investors.

Risk Assessment

Risk Level: low — The filing is procedural and does not disclose any new financial or operational risks.

Key Numbers

Key Players & Entities

FAQ

What specific matters were submitted to a vote of Opus Genetics' security holders on April 30, 2025?

The provided 8-K filing does not specify the exact matters that were submitted to a vote of security holders.

What was the outcome of the vote on April 30, 2025?

The filing does not disclose the results or outcomes of the shareholder vote.

When was Opus Genetics, Inc. incorporated?

Opus Genetics, Inc. was incorporated in Delaware.

What is the principal executive office address for Opus Genetics, Inc.?

The principal executive offices are located at 8 Davis Drive, Suite 220, Durham, NC 27709.

Has Opus Genetics, Inc. had previous names?

Yes, Opus Genetics, Inc. was formerly known as Ocuphire Pharma, Inc. (name change effective 20201109), Rexahn Pharmaceuticals, Inc. (name change effective 20050516), and Corporate Road Show Dot Com Inc (name change effective 20030423).

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on May 1, 2025 regarding Opus Genetics, Inc. (IRD).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing